Presence and Onset of Chronic Kidney Disease as a Factor Involved in the Poor Prognosis of Patients with Essential Thrombocythemia

Table 3

Univariable and multivariable analyses of predictors of overall survival in patients without chronic kidney disease at the time of ET diagnosis.

Variables	Univariable			Multivariable
	HR	95% CI	value	HR	95% CI	value
Age ≥60 years	3.402	0.409–28.290	0.257
Gender (male)	4.027	0.776–20.890	0.097
WBC ≥11 × 10^9/L	1.370	0.304–6.181	0.682
Plt ≥1000 × 10^9/L	6.015	1.147–31.55	0.034	2.735	0.322–23.210	0.357
CRP ≥0.30 mg/dL	4.786	0.961–23.830	0.056
Uric acid ≥7.0 mg/dL	2.570	0.298–22.180	0.391
JAK2V617F mutation	1.644	0.317–8.519	0.554
Chromosome abnormality	All patients with chromosome abnormalities survived
History of thrombosis	2.750	0.613–12.340	0.187
History of hemorrhagic events	2.493	0.290–21.440	0.406
Cardiovascular risk factors	2.262	0.431–11.870	0.335
Splenomegaly	5.452	1.219–24.390	0.026	2.809	0.420–18.780	0.287
Antiplatelet therapy	0.586	0.068–5.071	0.627
Cytoreductive therapy with HU	0.337	0.061–1.843	0.209
Cytoreductive therapy with ANA	1.459	0.267–7.974	0.663
Onset of CKD	11.550	2.074–64.280	0.005	9.155	1.542–54.370	0.015

ANA, anagrelide; CI, confidence interval; CKD, chronic kidney disease; ET, essential thrombocythemia; HU, hydroxyurea; HR, hazard ratio. values of <0.05 are highlighted in bold.